All Topics
All Topics
Technology
Technology
AI
AI
Business
Business
Entertainment
Entertainment
News
News
Programming
Programming
Science
Science
Design
Design
Environment
Environment
Finance
Finance
Crypto
Crypto
Politics
Politics
Sports
Sports
Education
Education
Gaming
Gaming
Art
Art
Music
Music
Health
Health
Security
Security
Books
Books
Food
Food
Travel
Travel
Personal
Personal
Bluesky
Twitter

A Study of Trastuzumab Rezetecan in Combination With Adebrelimab Versus Investigator's Choice of Therapy in Subjects With Residual Triple Negative Breast Cancer

8d agoen
Read on clinicaltrials.gov

From the article

Conditions : Triple Negative Breast Cancer Interventions : Drug: Trastuzumab Rezetecan for Injection; Drug: Adebrelimab Injection; Drug: Capecitabine tablets; Drug: Pembrolizumab injection Sponsors : Suzhou Suncadia Biopharmaceuticals Co., Ltd. Not yet recruiting
Continue reading on clinicaltrials.gov

You might also wanna read

Comments

Sign in to join the conversation.

No comments yet. Be the first.